Research programme: monoclonal antibodies - TaiMed Biologics/Rockefeller University

Drug Profile

Research programme: monoclonal antibodies - TaiMed Biologics/Rockefeller University

Alternative Names: LM 52; TMB 360; TMB-365

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aaron Diamond AIDS Research Center
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 20 May 2016 TaiMed Biologics in-licenses TMB 365-relevant technology platform from the Aaron Diamond AIDS Research Center (before May 2016; TaiMed Biologics website, May 2016)
  • 20 May 2016 Preclinical trials in HIV infections in Taiwan (Parenteral) (before May 2016; TaiMed Biologics pipeline, May 2016)
  • 20 May 2016 TaiMed Biologics plans a phase I trial for HIV infections in Taiwan (TaiMed Biologics pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top